Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2016

View Archived Issues

LOXL3 null mutations are associated with early-onset high myopia

Patrys acquires license to preclinical novel anti-DNA antibodies discovered at Yale

Portola releases topline phase III data from APEX trial of betrixaban

Anika Therapeutics receives CE Mark approval for Cingal

Topline phase IIb results for fispemifene in symptomatic secondary hypogonadism

Successful topline results reported from phase II trial of BL-8040 in AML

Zykadia receives approval in Japan

Vigabatrin approved in Japan

Sanofi obtains Japanese approval of primaquine for malaria

First patient enrolled in phase I clinical trial of TSR-042

Positive topline results from pivotal phase III study of ferric citrate

Preliminary phase II results for APL-1202 in high-risk NMIBC patients

Emulate raises funding to translate Organs-on-Chips technology into Human Emulation System

Bristol-Myers Squibb patents GPR120 agonists

Spero Therapeutics describes antibiotic agents

Kite Pharma initiates phase I/II trial of KTE-C19 for pediatric ALL

Samumed discloses Wnt singaling inhibitors

Merck & Co. presents BACE inhibitors

Griffith University reports development of antiviral agents

Janssen Pharma submits application in Japan for Stelara

Vedanta Biosciences in license agreement for immune-boosting microbiome technology

FDA advisory committee votes in favor of Nuplazid

Onxeo closes acquisition of DNA Therapeutics

FDA issues complete response letter for safinamide

Rexahn Pharmaceuticals initiates phase Ib-IIa trial of RX-3117 in pancreatic and bladder cancer

Novel RAF kinase inhibitor shows promise for NSCLC

Ohr Pharmaceutical initiates phase III clinical program evaluating squalamine in wet AMD

OPKO Health receives complete response letter from FDA for calcifediol

Claudin-18 is associated with poor prognosis in cervical adenocarcinoma